Patient characteristics
| Characteristic . | PBC patients . | Post-DLI patients . |
|---|---|---|
| Total no. of patients | 54 | 5 |
| No. female/no. male | 50/4 | 2/3 |
| Median age, y, ± interquartile distance | 69 ± 5 | 55 ± 7 |
| Median duration of disease, y, ± interquartile distance | 16 ± 4.5 | NA |
| Advanced stage, no. of patients | 33 | NA |
| Mean ALT level, IU/L | 59.5 ± 40.6 | 47.8 ± 36.2 |
| Mean alkaline phosphatase level, IU/L, ± SD | 623.3 ± 816.8 | 89.6 ± 10.1 |
| Mean bilirubin level, μm, ± SD | 14.71 ± 11.97 | 10.26 ± 3.42 |
| Mean IgM level, g/L, ± SD | 3.061 ± 1.915 | 0.81 ± 0.466 |
| Mean IgG level, g/L, ± SD | 14.556 ± 4.611 | 9.252 ± 3.686 |
| UDCA therapy, no. of patients | 47 | NA |
| Characteristic . | PBC patients . | Post-DLI patients . |
|---|---|---|
| Total no. of patients | 54 | 5 |
| No. female/no. male | 50/4 | 2/3 |
| Median age, y, ± interquartile distance | 69 ± 5 | 55 ± 7 |
| Median duration of disease, y, ± interquartile distance | 16 ± 4.5 | NA |
| Advanced stage, no. of patients | 33 | NA |
| Mean ALT level, IU/L | 59.5 ± 40.6 | 47.8 ± 36.2 |
| Mean alkaline phosphatase level, IU/L, ± SD | 623.3 ± 816.8 | 89.6 ± 10.1 |
| Mean bilirubin level, μm, ± SD | 14.71 ± 11.97 | 10.26 ± 3.42 |
| Mean IgM level, g/L, ± SD | 3.061 ± 1.915 | 0.81 ± 0.466 |
| Mean IgG level, g/L, ± SD | 14.556 ± 4.611 | 9.252 ± 3.686 |
| UDCA therapy, no. of patients | 47 | NA |
UDCA indicates ursodeoxycholic acid; NA, not applicable.